Assessment of Serum Neutralizing Antibody Titers against Foot-and-Mouth Disease Virus A and O in Young Colostrum-Fed Dairy Calves

Authors

  • B Alirezaie Human Viral Vaccines Department, Razi Vaccine and Serum Research Institute, Karaj, Iran
  • G Afshari Faculty of Veterinary Medicine, Tehran University, Tehran, Iran
  • H Mahravani-Behbahani Foot-and-mouth Disease Vaccine Department, Razi Vaccine and Serum Research Institute, Karaj, Iran
  • MH Chahe Animal Viral Vaccines Department, Razi Vaccine and Serum Research Institute, Karaj, Iran
Abstract:

This article doesn't have abstract

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Organic Circulation and persistence of Foot – and – Mouth disease virus type O in guinea pig

Since, the most susceptible laboratory animal to Foot–and–Mouth disease virus (FMDV) is guinea pig, and then one milliliter of FMDV type (O) concentrations of 106-106.5 TCID50was inoculated intradermally (ID) to 10 plantar surface of guinea pig (right side). Guinea pig adapted virus has been prepared after generalization phase, and then one milliliter of virus was inoculated intradermally to 30...

full text

Developing Vaccines against Foot-and-Mouth Disease: a Biotechnological Approach

Foot-and-mouth disease (FMD) is a contagious viral disease of livestock with significant economic effect. It is prevalent in various regions of Asia, Africa, and South America. The causative agent of this disease is called foot-and-mouth disease virus (FMDV), which is a member of Aphthovirus genus. Vaccination is an effective technique to prevent the complications of FMD and to eradicate the di...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue None

pages  35- 38

publication date 2009-10

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023